Skip to Main Content
Contribute Try STAT+ Today

“You’ve been a bad boy,” Moses Znaimer, the bespectacled media mogul often referred to as Canada’s Ted Turner, said to the wheeled robot rolling stintingly toward him. “Please, explain yourself.”

It was 2015, and Znaimer was onstage at the Royal Conservatory in Toronto hosting Ideacity, a north-of-the-border gathering of big thinkers designed to rival TED. It was exactly the kind of place one might expect to find Aubrey de Grey, the famed gerontologist known for popularizing the hitherto heretical notion that aging was not inevitable but in fact a treatable disease. And indeed he should have been there, except de Grey had missed his red eye from San Francisco the night before. So here he was now, beamed in via Skype to the screen of a robotic surrogate making its way across the stage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment